Marker Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Marker Therapeutics Inc (MRKR) Price Performance

Marker Therapeutics Inc (MRKR) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.45, down 5.84% from the previous close.

Over the past year, MRKR has traded between a low of $0.85 and a high of $2.19. The stock has gained 16.0% over this period. It is currently 33.8% below its 52-week high.

Marker Therapeutics Inc has a market capitalization of $22.34M.

About Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Compare Marker Therapeutics Inc

Side-by-side comparison against top Healthcare peers.